Xiaojin Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaojin Gao has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Yuejin Yang
Department of Cardiology State Key Laboratory of Cardiovascular Disease National Center for Cardiovascular Diseases Fuwai Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing People's Republic of China
18 shared publications Jingang Yang
Affiliation Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
12 shared publicationsHaiyan Xu
Affiliation Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
11 shared publicationsYang Wang
Department of Medical Research and Biometrics Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
11 shared publicationsWei Li
Medical Research & Biometrics Center, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Beijing, China
9 shared publications- Jin-Gang Yang
Health Education Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
8 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1) , 449
Artificial intelligence–enhanced management system for secondary prevention of coronary heart disease: a randomized clinical trial
Background: Secondary prevention of coronary heart disease (CHD) remains suboptimal due to fragmented care and therapeutic inertia. While digital health interventions offer a promising strategy, few existing tools provide comprehensive, closed-loop management of multidimensional risk factors without increasing clinician workload. This study aimed to evaluate the efficacy of an artificial intelligence (AI)–enhanced management system (AIM-CHD) in improving multidimensional risk factor control among patients with CHD. Methods: This single-center, open-label, parallel-group, randomized clinical trial was conducted from November 2024 to June 2025 in China. A total of 1100 adults with confirmed CHD were randomized 1:1 to receive either the AIM-CHD intervention ( n = 549) or usual care ( n = 551) for 3 months. The AIM-CHD system featured automated multi-source data capture, guideline-directed risk stratification, and closed-loop feedback via smartphone. The primary outcome was the low-density lipoprotein cholesterol (LDL-C) level at 3 months. Secondary outcomes included goal attainment rates for LDL-C (< 70 mg/dL) and blood pressure (BP, < 130/80 mm Hg), glycated hemoglobin, smoking cessation, body mass index (BMI), medication adherence, and a composite cardiovascular endpoint at 3 months. Analysis was performed on an intention-to-treat (ITT) basis. Results: Of 1100 randomized participants (mean age 61 years; 75.3% male), 943 (85.7%) completed the 3-month follow-up. The intervention group achieved a significantly lower mean LDL-C level compared with the control group (60.4 ± 23.4 vs. 63.7 ± 26.0 mg/dL), with an adjusted mean difference of − 3.2 mg/dL (95% CI, − 6.2 to − 0.3; p = 0.03). Furthermore, participants in the intervention group were more likely to achieve the LDL-C target (71% vs. 64%; RR, 1.10; 95% CI, 1.01–1.20; p = 0.03) and the BP target (45% vs. 35%; RR, 1.27; 95% CI, 1.09–1.48; p = 0.002). No significant differences were observed for HbA1c, BMI, or medication adherence. Conclusions: The AIM-CHD system significantly improved short-term lipid and BP control compared with usual care. These findings support interoperable, low-burden digital management systems as a scalable strategy in routine secondary prevention. Trial registration: ClinicalTrials.gov Identifier: NCT06686056. Registered on 11 November 2024.
- 18 August 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1) , 449
Open AccessArtificial intelligence–enhanced management system for secondary prevention of coronary heart disease: a randomized clinical trial
Background: Secondary prevention of coronary heart disease (CHD) remains suboptimal due to fragmented care and therapeutic inertia. While digital health interventions offer a promising strategy, few existing tools provide comprehensive, closed-loop management of multidimensional risk factors without increasing clinician workload. This study aimed to evaluate the efficacy of an artificial intelligence (AI)–enhanced management system (AIM-CHD) in improving multidimensional risk factor control among patients with CHD. Methods: This single-center, open-label, parallel-group, randomized clinical trial was conducted from November 2024 to June 2025 in China. A total of 1100 adults with confirmed CHD were randomized 1:1 to receive either the AIM-CHD intervention ( n = 549) or usual care ( n = 551) for 3 months. The AIM-CHD system featured automated multi-source data capture, guideline-directed risk stratification, and closed-loop feedback via smartphone. The primary outcome was the low-density lipoprotein cholesterol (LDL-C) level at 3 months. Secondary outcomes included goal attainment rates for LDL-C (< 70 mg/dL) and blood pressure (BP, < 130/80 mm Hg), glycated hemoglobin, smoking cessation, body mass index (BMI), medication adherence, and a composite cardiovascular endpoint at 3 months. Analysis was performed on an intention-to-treat (ITT) basis. Results: Of 1100 randomized participants (mean age 61 years; 75.3% male), 943 (85.7%) completed the 3-month follow-up. The intervention group achieved a significantly lower mean LDL-C level compared with the control group (60.4 ± 23.4 vs. 63.7 ± 26.0 mg/dL), with an adjusted mean difference of − 3.2 mg/dL (95% CI, − 6.2 to − 0.3; p = 0.03). Furthermore, participants in the intervention group were more likely to achieve the LDL-C target (71% vs. 64%; RR, 1.10; 95% CI, 1.01–1.20; p = 0.03) and the BP target (45% vs. 35%; RR, 1.27; 95% CI, 1.09–1.48; p = 0.002). No significant differences were observed for HbA1c, BMI, or medication adherence. Conclusions: The AIM-CHD system significantly improved short-term lipid and BP control compared with usual care. These findings support interoperable, low-burden digital management systems as a scalable strategy in routine secondary prevention. Trial registration: ClinicalTrials.gov Identifier: NCT06686056. Registered on 11 November 2024.
- Open Access
- 7 August 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (8) , e0001529
CAMI-DM: Development and validation of a multi-algorithm model for in-hospital mortality risk prediction in diabetic patients with acute myocardial infarction — The China acute myocardial infarction registry
Patients with diabetes constitute a substantial proportion of those with acute myocardial infarction (AMI) and exhibit distinct pathophysiological characteristics. However, existing guideline-recommended traditional and generic risk prediction models show limited performance in this specific population. Based on the China Acute Myocardial Infarction (CAMI) registry, 6,091 diabetic patients with AMI were enrolled and randomly divided into training and test sets (8:2). A comprehensive set of 62 multidimensional candidate features was extracted, and three feature selection strategies were applied to develop 12 machine learning models across six algorithm categories. All models underwent hyperparameter tuning via five-fold cross-validation in the training set, with the optimal combination selected according to the area under the receiver operating characteristic curve (AUROC). Two post-hoc ensemble strategies—stacking and probability averaging—were then employed to explore various combinations of top-performing models from different algorithm categories. Across six algorithm categories, the predictive models developed using 11 features selected by Elastic Net had the optimal performance. After evaluating various fusion strategies, the ensembled GLM + TabNet model was ultimately selected as the CAMI-DM model 2.0, achieving an AUROC of 0.875 in the test set. To balance the predictive performance and model simplicity, the CAMI-DM model 1.0 adopted a linear framework and was developed using five features from consensus feature selection Strategy, with an AUROC of 0.821 in the test set. Comparative analyses revealed that the CAMI-DM 2.0 outperformed CAMI-DM 1.0 in terms of discrimination, accuracy, calibration, and clinical net benefit. Furthermore, CAMI-DM 1.0, with its simplified structure, still outperformed the GRACE score in the overall predictive performance and generalizability. This study focused on the specific population of AMI patients with diabetes, and for the first time developed two dedicated models to predict in-hospital mortality risk.
- 7 August 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (8) , e0001529
Open AccessCAMI-DM: Development and validation of a multi-algorithm model for in-hospital mortality risk prediction in diabetic patients with acute myocardial infarction — The China acute myocardial infarction registry
Patients with diabetes constitute a substantial proportion of those with acute myocardial infarction (AMI) and exhibit distinct pathophysiological characteristics. However, existing guideline-recommended traditional and generic risk prediction models show limited performance in this specific population. Based on the China Acute Myocardial Infarction (CAMI) registry, 6,091 diabetic patients with AMI were enrolled and randomly divided into training and test sets (8:2). A comprehensive set of 62 multidimensional candidate features was extracted, and three feature selection strategies were applied to develop 12 machine learning models across six algorithm categories. All models underwent hyperparameter tuning via five-fold cross-validation in the training set, with the optimal combination selected according to the area under the receiver operating characteristic curve (AUROC). Two post-hoc ensemble strategies—stacking and probability averaging—were then employed to explore various combinations of top-performing models from different algorithm categories. Across six algorithm categories, the predictive models developed using 11 features selected by Elastic Net had the optimal performance. After evaluating various fusion strategies, the ensembled GLM + TabNet model was ultimately selected as the CAMI-DM model 2.0, achieving an AUROC of 0.875 in the test set. To balance the predictive performance and model simplicity, the CAMI-DM model 1.0 adopted a linear framework and was developed using five features from consensus feature selection Strategy, with an AUROC of 0.821 in the test set. Comparative analyses revealed that the CAMI-DM 2.0 outperformed CAMI-DM 1.0 in terms of discrimination, accuracy, calibration, and clinical net benefit. Furthermore, CAMI-DM 1.0, with its simplified structure, still outperformed the GRACE score in the overall predictive performance and generalizability. This study focused on the specific population of AMI patients with diabetes, and for the first time developed two dedicated models to predict in-hospital mortality risk.
- Open Access
Development and retrospective validation of SCOUT: scalable clinical oversight of large language models via uncertainty triangulation
Large language models (LLMs) are increasingly used in clinical workflows, yet requiring clinician review of every AI output negates the efficiency gains that motivate their adoption. We present SCOUT (Scalable Clinical Oversight via Uncertainty Triangulation), a model-agnostic meta-verification framework that selectively defers unreliable LLM predictions to clinicians by triangulating three orthogonal signals: model heterogeneity, stochastic inconsistency, and reasoning critique. In this retrospective development and validation study, we derived the framework on a discovery cohort (n = 405) and validated it across three clinically distinct tasks using 4 independent retrospective cohorts: coronary heart disease subtyping (n = 2,271), liver cancer screening from radiology reports (n = 3,373), and diseased coronary vessel counting (n = 286). SCOUT reduced the volume of cases requiring human review by 45% to 83%, with projected final accuracy of 99.1% to 100.0% assuming expert correction of all flagged cases. SCOUT provides a scalable, retrospectively validated approach for deploying generative AI in clinical medicine without compromising patient safety. Prospective randomized validation is underway to confirm real-world clinical utility.
Open AccessDevelopment and retrospective validation of SCOUT: scalable clinical oversight of large language models via uncertainty triangulation
Large language models (LLMs) are increasingly used in clinical workflows, yet requiring clinician review of every AI output negates the efficiency gains that motivate their adoption. We present SCOUT (Scalable Clinical Oversight via Uncertainty Triangulation), a model-agnostic meta-verification framework that selectively defers unreliable LLM predictions to clinicians by triangulating three orthogonal signals: model heterogeneity, stochastic inconsistency, and reasoning critique. In this retrospective development and validation study, we derived the framework on a discovery cohort (n = 405) and validated it across three clinically distinct tasks using 4 independent retrospective cohorts: coronary heart disease subtyping (n = 2,271), liver cancer screening from radiology reports (n = 3,373), and diseased coronary vessel counting (n = 286). SCOUT reduced the volume of cases requiring human review by 45% to 83%, with projected final accuracy of 99.1% to 100.0% assuming expert correction of all flagged cases. SCOUT provides a scalable, retrospectively validated approach for deploying generative AI in clinical medicine without compromising patient safety. Prospective randomized validation is underway to confirm real-world clinical utility.
- Open Access
- 26 November 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1) , 721
Trends and effectiveness of digital health management in postdischarge coronary artery disease across COVID19 pandemic
The effectiveness of digital health management (DM) in post-discharge care for patients with coronary artery disease (CAD) remains insufficiently explored, particularly across public health emergencies. A total of 24,129 patients with CAD enrolled in the HeartMed Digital Management System were divided into DM or conventional management groups based on patient preference, and categorized into pre-COVID-19 (n = 13,473; 16.7% DM), COVID-19 (n = 5173; 80.3% DM), and post-COVID-19 (n = 5483; 86.2% DM) eras according to enrollment dates. For the primary endpoint, digital healthcare was significantly associated with lower all-cause mortality risk across all three periods after adjustment (HR: pre-COVID 0.23; COVID 0.52; post-COVID 0.58; all p < 0.001). No significant interaction was found in the protective effect of DM among the three eras (all interaction p > 0.05). Similar trends were observed for the secondary endpoints—readmission, MACE, and MACCE. Across all three pandemic phases, DM was consistently associated with improved clinical outcomes in post-discharge CAD populations.
- 26 November 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1) , 721
Open AccessTrends and effectiveness of digital health management in postdischarge coronary artery disease across COVID19 pandemic
The effectiveness of digital health management (DM) in post-discharge care for patients with coronary artery disease (CAD) remains insufficiently explored, particularly across public health emergencies. A total of 24,129 patients with CAD enrolled in the HeartMed Digital Management System were divided into DM or conventional management groups based on patient preference, and categorized into pre-COVID-19 (n = 13,473; 16.7% DM), COVID-19 (n = 5173; 80.3% DM), and post-COVID-19 (n = 5483; 86.2% DM) eras according to enrollment dates. For the primary endpoint, digital healthcare was significantly associated with lower all-cause mortality risk across all three periods after adjustment (HR: pre-COVID 0.23; COVID 0.52; post-COVID 0.58; all p < 0.001). No significant interaction was found in the protective effect of DM among the three eras (all interaction p > 0.05). Similar trends were observed for the secondary endpoints—readmission, MACE, and MACCE. Across all three pandemic phases, DM was consistently associated with improved clinical outcomes in post-discharge CAD populations.
- Open Access
- 3 October 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-12
Occupational status and outcomes in acute myocardial infarction: a prospective cohort study
While Western studies often show an inverse association between occupational status and cardiovascular mortality, its impact on acute myocardial infarction (AMI) characteristics and prognosis in Eastern middle-income countries remains unclear. Using data from the multi-center prospective China Acute Myocardial Infarction (CAMI) registry from January 2013 to January 2016, 11,318 admission AMI patients aged 18–60 years were stratified by occupation: white-collar (22.1%), blue-collar (23.4%), farmers (44.3%), and unemployed (10.1%). White- and blue-collar workers comprised the “stable employment” group; farmers and unemployed comprised “unstable employment.” We compared risk factors, treatments, and clinical outcomes. Multivariable Cox regression assessed occupational impacts on in-hospital and 2-year post-discharge all-cause mortality, progressively adjusting for demographics, self-reported risk histories and clinically measured parameters, treatments and hospital level. Stable employment groups (particularly white-collar patients) had higher baseline cardiovascular risks but less severe clinical presentation and higher reperfusion rates than unstable groups. No significant in-hospital mortality differences were observed after full adjustment. At 2-year follow-up, white-collar patients initially demonstrated 50% lower post-discharge mortality versus unemployed after demographic adjustment (HR 0.487; 95% CI 0.257–0.924). This association weakened with adjustment for risk histories/clinical characteristics (HR 0.506; 95% CI 0.266–0.964) and became non-significant after including treatment/hospital-level factors (HR 0.519; 95% CI 0.271–1.021). Neither blue-collar workers (fully adjusted HR 0.848; 95% CI 0.474–1.516) nor farmers (fully adjusted HR 1.164; 95% CI 0.702–1.931) showed significant mortality differences versus unemployed. Critically, unstable employment independently predicted higher 2-year post-discharge mortality after full adjustment (HR 1.639; 95% CI 1.169–2.298). Stable employment (White- and Blue-collar) was associated with significantly higher cardiovascular risk factors but better long-term outcomes compared to farmers and the unemployed. This trend was particularly pronounced among White-collar workers.
- 3 October 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-12
Open AccessOccupational status and outcomes in acute myocardial infarction: a prospective cohort study
While Western studies often show an inverse association between occupational status and cardiovascular mortality, its impact on acute myocardial infarction (AMI) characteristics and prognosis in Eastern middle-income countries remains unclear. Using data from the multi-center prospective China Acute Myocardial Infarction (CAMI) registry from January 2013 to January 2016, 11,318 admission AMI patients aged 18–60 years were stratified by occupation: white-collar (22.1%), blue-collar (23.4%), farmers (44.3%), and unemployed (10.1%). White- and blue-collar workers comprised the “stable employment” group; farmers and unemployed comprised “unstable employment.” We compared risk factors, treatments, and clinical outcomes. Multivariable Cox regression assessed occupational impacts on in-hospital and 2-year post-discharge all-cause mortality, progressively adjusting for demographics, self-reported risk histories and clinically measured parameters, treatments and hospital level. Stable employment groups (particularly white-collar patients) had higher baseline cardiovascular risks but less severe clinical presentation and higher reperfusion rates than unstable groups. No significant in-hospital mortality differences were observed after full adjustment. At 2-year follow-up, white-collar patients initially demonstrated 50% lower post-discharge mortality versus unemployed after demographic adjustment (HR 0.487; 95% CI 0.257–0.924). This association weakened with adjustment for risk histories/clinical characteristics (HR 0.506; 95% CI 0.266–0.964) and became non-significant after including treatment/hospital-level factors (HR 0.519; 95% CI 0.271–1.021). Neither blue-collar workers (fully adjusted HR 0.848; 95% CI 0.474–1.516) nor farmers (fully adjusted HR 1.164; 95% CI 0.702–1.931) showed significant mortality differences versus unemployed. Critically, unstable employment independently predicted higher 2-year post-discharge mortality after full adjustment (HR 1.639; 95% CI 1.169–2.298). Stable employment (White- and Blue-collar) was associated with significantly higher cardiovascular risk factors but better long-term outcomes compared to farmers and the unemployed. This trend was particularly pronounced among White-collar workers.
- Open Access
- 23 September 2025
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 61, 101808
Atorvastatin pretreatment, ST-segment resolution and long-term prognosis for ST-segment elevation myocardial infarction with primary percutaneous coronary intervention
- 23 September 2025
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 61, 101808
Open AccessAtorvastatin pretreatment, ST-segment resolution and long-term prognosis for ST-segment elevation myocardial infarction with primary percutaneous coronary intervention
- Open Access
Effectiveness of an AI-enhanced management system for coronary heart disease (AIM-CHD): rationale and design of a single-centre, open-label, randomised, parallel-controlled trial
Introduction Effective secondary prevention of coronary heart disease (CHD) is often hindered by limited healthcare resources and poor patient adherence. We therefore developed an artificial intelligence (AI)-enhanced CHD management platform (AIM-CHD) that (i) automatically captures follow-up data through AI-driven voice calls, optical character recognition of laboratory reports and wearable sensor streams; (ii) enables closed-loop, automated risk factor management; and (iii) dynamically personalises follow-up intensity via continuously updated risk stratification and achievement of treatment targets. This trial aims to evaluate whether AIM-CHD improves risk factor control and reduces cardiovascular events compared with usual care. Methods and analysis In this prospective, single-centre, open-label, randomised controlled trial, 1100 CHD patients aged 18–85 years will be enrolled at Fuwai Hospital and randomised 1:1 to either the AIM-CHD group (n=550) or the usual care group (n=550) for a 3 month post-discharge intervention. The primary outcome is low-density lipoprotein cholesterol (LDL-C) level at 3 months. Secondary outcomes include target achievement for LDL-C and blood pressure, as well as glycosylated haemoglobin level, nonsmoking status, body mass index, composite cardiovascular endpoint and medication adherence. Ethics and dissemination Ethical approval was approved by the Ethics Committee of Fuwai Hospital on 4 November 2024 (2024-2422). The findings will be disseminated in peer-reviewed publications. An anonymised template of the written informed-consent form (Chinese and English versions) is available as Supplementary Material 1. Trial registration number ClinicalTrial, NCT06686056.
Open AccessEffectiveness of an AI-enhanced management system for coronary heart disease (AIM-CHD): rationale and design of a single-centre, open-label, randomised, parallel-controlled trial
Introduction Effective secondary prevention of coronary heart disease (CHD) is often hindered by limited healthcare resources and poor patient adherence. We therefore developed an artificial intelligence (AI)-enhanced CHD management platform (AIM-CHD) that (i) automatically captures follow-up data through AI-driven voice calls, optical character recognition of laboratory reports and wearable sensor streams; (ii) enables closed-loop, automated risk factor management; and (iii) dynamically personalises follow-up intensity via continuously updated risk stratification and achievement of treatment targets. This trial aims to evaluate whether AIM-CHD improves risk factor control and reduces cardiovascular events compared with usual care. Methods and analysis In this prospective, single-centre, open-label, randomised controlled trial, 1100 CHD patients aged 18–85 years will be enrolled at Fuwai Hospital and randomised 1:1 to either the AIM-CHD group (n=550) or the usual care group (n=550) for a 3 month post-discharge intervention. The primary outcome is low-density lipoprotein cholesterol (LDL-C) level at 3 months. Secondary outcomes include target achievement for LDL-C and blood pressure, as well as glycosylated haemoglobin level, nonsmoking status, body mass index, composite cardiovascular endpoint and medication adherence. Ethics and dissemination Ethical approval was approved by the Ethics Committee of Fuwai Hospital on 4 November 2024 (2024-2422). The findings will be disseminated in peer-reviewed publications. An anonymised template of the written informed-consent form (Chinese and English versions) is available as Supplementary Material 1. Trial registration number ClinicalTrial, NCT06686056.
Asthma and risk of degenerative valvular heart disease: a prospective cohort study
Background Asthma has been associated with the development and progression of various cardiovascular diseases but its relationship with degenerative valvular heart disease (VHD) remains unclear. This study investigated the association between asthma and incident degenerative VHD, including aortic stenosis (AS), aortic regurgitation (AR), mitral regurgitation (MR) and pulmonary regurgitation (PR). Methods We analysed 483 735 participants from the UK Biobank (median age 56.5 years; 45.2% male) who were free of VHD at baseline. Asthma status was self-reported at recruitment. Incident VHD was ascertained through hospital admission and mortality records using International Classification of Diseases, Tenth Revision codes. Cox proportional hazards models were used to estimate HRs and 95% CIs for each VHD subtype, adjusting for demographic, lifestyle and clinical covariates. Sensitivity analyses accounted for asthma medications, duration of asthma and competing risks. Results Over a median follow-up of 13.8 years, 5388 participants developed AS, 2650 AR, 6088 MR and 821 PR. Asthma was associated with increased risk of AS (HR 1.31; 95% CI 1.21 to 1.41), AR (HR 1.24; 95% CI 1.11 to 1.39), MR (HR 1.19; 95% CI 1.10 to 1.28) and PR (HR 1.34; 95% CI 1.10 to 1.62). The association with AR was attenuated after adjusting for asthma medications (HR 1.12; 95% CI 0.97 to 1.30). Results were robust across multiple sensitivity analyses, including adjustment for asthma duration and exclusion of participants with pre-existing cardiovascular disease. Conclusions Asthma is independently associated with a modestly increased risk of several degenerative VHDs, particularly aortic and mitral valve diseases. These findings suggest a potential shared inflammatory pathway and highlight the need for heightened cardiovascular surveillance in individuals with asthma.
Asthma and risk of degenerative valvular heart disease: a prospective cohort study
Background Asthma has been associated with the development and progression of various cardiovascular diseases but its relationship with degenerative valvular heart disease (VHD) remains unclear. This study investigated the association between asthma and incident degenerative VHD, including aortic stenosis (AS), aortic regurgitation (AR), mitral regurgitation (MR) and pulmonary regurgitation (PR). Methods We analysed 483 735 participants from the UK Biobank (median age 56.5 years; 45.2% male) who were free of VHD at baseline. Asthma status was self-reported at recruitment. Incident VHD was ascertained through hospital admission and mortality records using International Classification of Diseases, Tenth Revision codes. Cox proportional hazards models were used to estimate HRs and 95% CIs for each VHD subtype, adjusting for demographic, lifestyle and clinical covariates. Sensitivity analyses accounted for asthma medications, duration of asthma and competing risks. Results Over a median follow-up of 13.8 years, 5388 participants developed AS, 2650 AR, 6088 MR and 821 PR. Asthma was associated with increased risk of AS (HR 1.31; 95% CI 1.21 to 1.41), AR (HR 1.24; 95% CI 1.11 to 1.39), MR (HR 1.19; 95% CI 1.10 to 1.28) and PR (HR 1.34; 95% CI 1.10 to 1.62). The association with AR was attenuated after adjusting for asthma medications (HR 1.12; 95% CI 0.97 to 1.30). Results were robust across multiple sensitivity analyses, including adjustment for asthma duration and exclusion of participants with pre-existing cardiovascular disease. Conclusions Asthma is independently associated with a modestly increased risk of several degenerative VHDs, particularly aortic and mitral valve diseases. These findings suggest a potential shared inflammatory pathway and highlight the need for heightened cardiovascular surveillance in individuals with asthma.
- Open Access
- 23 July 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1) , 1-12
Effectiveness of digital healthcare to improve clinical outcomes in discharged patients with coronary artery disease
Post-discharge management of coronary artery disease (CAD) remains clinically challenging, with digital healthcare’s efficacy underexplored. This study analyzed 16,797 CAD patients enrolled in the HeartMed Digital Management System (June 2018–September 2022), comparing outcomes between a digital management (DM, n = 4,713) and conventional management (CM, n = 12,084) cohort over 12 months. Cox models adjusted for confounders revealed significantly reduced all-cause mortality in the DM group (1.6% vs. 2.7%; HR 0.58, 95% CI 0.45–0.75, p < 0.001) and lower risks for major adverse cardiovascular events (MACCE: 6.4% vs. 9.2%; HR 0.67, 0.59–0.77, p < 0.001), cardiovascular death (HR 0.70, 0.51–0.95), myocardial infarction (HR 0.38, 0.29–0.50), recurrent angina (HR 0.75, 0.65–0.87), revascularization (HR 0.84, 0.71–0.99), and readmissions (HR 0.76, 0.68–0.84) (p < 0.05 for all). Digital healthcare demonstrates superior post-discharge optimization of CAD outcomes, significantly attenuating mortality and morbidity.
- 23 July 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1) , 1-12
Open AccessEffectiveness of digital healthcare to improve clinical outcomes in discharged patients with coronary artery disease
Post-discharge management of coronary artery disease (CAD) remains clinically challenging, with digital healthcare’s efficacy underexplored. This study analyzed 16,797 CAD patients enrolled in the HeartMed Digital Management System (June 2018–September 2022), comparing outcomes between a digital management (DM, n = 4,713) and conventional management (CM, n = 12,084) cohort over 12 months. Cox models adjusted for confounders revealed significantly reduced all-cause mortality in the DM group (1.6% vs. 2.7%; HR 0.58, 95% CI 0.45–0.75, p < 0.001) and lower risks for major adverse cardiovascular events (MACCE: 6.4% vs. 9.2%; HR 0.67, 0.59–0.77, p < 0.001), cardiovascular death (HR 0.70, 0.51–0.95), myocardial infarction (HR 0.38, 0.29–0.50), recurrent angina (HR 0.75, 0.65–0.87), revascularization (HR 0.84, 0.71–0.99), and readmissions (HR 0.76, 0.68–0.84) (p < 0.05 for all). Digital healthcare demonstrates superior post-discharge optimization of CAD outcomes, significantly attenuating mortality and morbidity.
- Open Access
- 20 May 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-12
Role of heavy sweating for ST-segment elevation myocardial infarction: analysis of the China Acute Myocardial Infarction registry
Sweating in individuals with suspected cardiac chest pain indicates a greater risk of experiencing ST-segment elevation myocardial infarction (STEMI). Nevertheless, the relationship between sweating and clinical outcomes remains inadequately explored. From 2013 through 2016, 19112 patients with STEMI enrolled in the China Acute Myocardial Infarction registry. Heavy sweating was evaluated on admission and usually judged by dampen clothing. Thrombolysis in Myocardial Infarction (TIMI) flow and ST-segment resolution (STR) were used to evaluated the myocardial reperfusion after primary percutaneous myocardial infarction (PCI). The primary outcome was all-cause death during hospitalization and at 24 months. Thirteen thousand, four hundred twenty-two patients (70.2%) presented heavy sweating, that was associated with age < 65 years, severe chest pain, current smoking status, and heart rates < 100 bpm on admission. Heavy sweating group was more likely to achieve primary PCI (44.7% vs 32.9%) but shown similar rates of post-PCI TIMI 3 flow (95.5% vs 94.1%) and STR ≥ 50% (79.8% vs 78.2%). After multivariable analysis, heavy sweating was significantly linked to lower in-hospital (5.9% vs 8.6%, odds ratio [OR]: 0.81, 95% confidence interval [CI]: 0.72–0.92) and 24-month mortality (11.0% vs 17.2%, hazard ratio [HR]: 0.75, 95% CI: 0.69–0.82). Even among patients undergoing primary PCI who achieved successful myocardial reperfusion, this short- (2.5% vs 4.2%, OR: 0.60, 95% CI: 0.45–0.80) and long-term (5.9% vs 8.7%, HR: 0.68, 95% CI: 0.56–0.83) prognostic significance remained robust. For STEMI, the presence of heavy sweating was associated with lower mortality regardless of successful primary PCI, which highlight the potential for early risk stratification based on the sweating presentation. https//www.clinicaltrials.gov. Unique identifier: NCT01874691. Registered 11/06/2013.
- 20 May 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-12
Open AccessRole of heavy sweating for ST-segment elevation myocardial infarction: analysis of the China Acute Myocardial Infarction registry
Sweating in individuals with suspected cardiac chest pain indicates a greater risk of experiencing ST-segment elevation myocardial infarction (STEMI). Nevertheless, the relationship between sweating and clinical outcomes remains inadequately explored. From 2013 through 2016, 19112 patients with STEMI enrolled in the China Acute Myocardial Infarction registry. Heavy sweating was evaluated on admission and usually judged by dampen clothing. Thrombolysis in Myocardial Infarction (TIMI) flow and ST-segment resolution (STR) were used to evaluated the myocardial reperfusion after primary percutaneous myocardial infarction (PCI). The primary outcome was all-cause death during hospitalization and at 24 months. Thirteen thousand, four hundred twenty-two patients (70.2%) presented heavy sweating, that was associated with age < 65 years, severe chest pain, current smoking status, and heart rates < 100 bpm on admission. Heavy sweating group was more likely to achieve primary PCI (44.7% vs 32.9%) but shown similar rates of post-PCI TIMI 3 flow (95.5% vs 94.1%) and STR ≥ 50% (79.8% vs 78.2%). After multivariable analysis, heavy sweating was significantly linked to lower in-hospital (5.9% vs 8.6%, odds ratio [OR]: 0.81, 95% confidence interval [CI]: 0.72–0.92) and 24-month mortality (11.0% vs 17.2%, hazard ratio [HR]: 0.75, 95% CI: 0.69–0.82). Even among patients undergoing primary PCI who achieved successful myocardial reperfusion, this short- (2.5% vs 4.2%, OR: 0.60, 95% CI: 0.45–0.80) and long-term (5.9% vs 8.7%, HR: 0.68, 95% CI: 0.56–0.83) prognostic significance remained robust. For STEMI, the presence of heavy sweating was associated with lower mortality regardless of successful primary PCI, which highlight the potential for early risk stratification based on the sweating presentation. https//www.clinicaltrials.gov. Unique identifier: NCT01874691. Registered 11/06/2013.